Bachem Holding AG (0QND.L) LSE
69.00
-1.77571(-2.51%)
Currency In CHF
- General
- Statistics
- Historical Data
- Profile
- Financials
69.00
-1.77571(-2.51%)
Currency In CHF
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2207
First IPO Date
December 03, 2015
| Name | Title | Pay | Year Born |
| Anne-Kathrin Stoller | Chief Executive Officer | 0 | 1974 |
| Daniel Grotzky | Head of Group Communications | 0 | N/A |
| Gunther Loidl | Chief Technology Officer | 0 | 1970 |
| Achim Pluckebaum | Chief Information Officer | 0 | N/A |
| Alain Schaffter | Chief Financial Officer | 0 | 1977 |
| Hans van Hees | Chief Operations Officer | 0 | 1969 |
| Michael Suter | Vice President of Global Accounting | 0 | N/A |
| Barbora Blaha | Head of Investor Relations | 0 | N/A |
| Torsten Wohr | Chief Commercial Officer | 0 | 1968 |
| Viviane Minden | Chief Human Resources Officer | 0 | N/A |
Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.